Stop TB Partnership

KNCV welcomes price reduction for second-line TB drugs

14 March 2013 - The Hague, Netherlands - KNCV Tuberculosis Foundation (KNCV) has welcomed the announcement by the Stop TB Partnership’s Global Drug Facility (GDF) that prices for several second-line TB drugs have been reduced.

In a statement, KNCV said that it will prioritize the roll-out of programmes that improve diagnostic capacity, build patient-support networks and increase multidrug-resistant TB (MDR-TB) treatment capacity in countries.

"The price reduction means more patients can be treated. This will substantially reduce human suffering," KNCV said.